Encelto™ (Revakinagene Taroretcel-Lwey) – Commercial Medical Benefit Drug Policyopen_in_new

UnitedHealthcare covers Encelto for adults (≥18) with non‑proliferative idiopathic macular telangiectasia type 2 and excludes proliferative/neovascular MacTel. Coverage requires an ophthalmologist prescription, submission of medical records confirming the diagnosis, monitoring for retinal tear/detachment, dosing per FDA labeling, is limited to one treatment per eye per lifetime, authorizations valid ≤60 days, and is subject to member plan/state/federal mandates.

"Documentation of dosing consistent with the United States Food and Drug Administration approved labeling."

Sign up to see full coverage criteria, indications, and limitations.